Using these models to examine the role of Ppm1d in HSC biology and the therapy of myeloid malignancies, we found that despite being an important regulator of HSC fitness, PPM1D is also a therapeutic target to augment the efficacy of cytotoxic chemotherapy and radiation. This evidence concerns the gene PPM1D and myeloid neoplasm.